Disease · MONDO_0007793

hypochondroplasia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypochondroplasia. Diseases, record MONDO_0007793. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0007793

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypochondroplasia; Open Targets
Open Targets ID: MONDO_0007793; Open Targets
Disease Ontology: DOID:0080041; Disease Ontology
MeSH: C562937; MeSH
NCI Thesaurus: C118697; NCI Thesaurus
Orphanet: ORPHA:429; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 3 drugs, from ClinicalTrials.gov; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VOSORITIDE	CHEMBL3707276	Protein	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
INFIGRATINIB	CHEMBL1852688	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
SOMATROPIN	CHEMBL1201621	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

Targets6

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FGFR1	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2260	Drugs and targets
FGFR2	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2263	Drugs and targets
FGFR3	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2261	Drugs and targets
FGFR4	Fibroblast growth factor receptor	1	Fibroblast growth factor receptor inhibitor	Phase 2/3	https://conductscience.org/library/genes/2264	Drugs and targets
GHR	Growth hormone receptor	1	Growth hormone receptor agonist	Phase 2	https://conductscience.org/library/genes/2690	Drugs and targets
NPR2	Atrial natriuretic peptide receptor 2	1	Atrial natriuretic peptide receptor B binding agent	Phase 3	https://conductscience.org/library/genes/4882	Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01111019	Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children	Phase 2	19	2019-02-15	Hypochondroplasia	SOMATROPIN	Its record names the disease	ClinicalTrials.gov
NCT07073014	Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia	Phase 3	140		Hypochondroplasia	VOSORITIDE	Its record names the disease	ClinicalTrials.gov
NCT07393373	Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia	Phase 2	135		Hypochondroplasia	INFIGRATINIB	Its record names the disease	ClinicalTrials.gov
NCT01435629	A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin		81		Genetic Disorder, Achondroplasia	SOMATROPIN	Its record names the disease	ClinicalTrials.gov
NCT06455059	Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia	Phase 3	81		Hypochondroplasia	VOSORITIDE	Its record names the disease	ClinicalTrials.gov
NCT07126262	A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months	Phase 2	60		Hypochondroplasia	VOSORITIDE	Its record names the disease	ClinicalTrials.gov
NCT04219007	Vosoritide for Selected Genetic Causes of Short Stature	Phase 2	56		Short Stature	VOSORITIDE	Its record names the disease	ClinicalTrials.gov
NCT06873035	An Interventional Study of Infigratinib in Children With Hypochondroplasia	Phase 2/3	24		Hypochondroplasia	INFIGRATINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42713641	DERIVED	1	PubMed
38813446	DERIVED	1	PubMed
25323764	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0007793

GET https://conductscience.org/api/diseases/v1/MONDO_0007793/drugs

API reference For AI assistants